SeaCrest Wealth Management LLC bought a new position in shares of Globus Medical, Inc. (NYSE:GMED – Get Rating) during the second quarter, HoldingsChannel.com reports. The firm bought 549 shares of the medical device company’s stock, valued at approximately $31,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Signaturefd LLC raised its stake in shares of Globus Medical by 93.8% in the first quarter. Signaturefd LLC now owns 345 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 167 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in shares of Globus Medical by 3,325.0% in the 2nd quarter. First Horizon Advisors Inc. now owns 548 shares of the medical device company’s stock valued at $30,000 after buying an additional 532 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of Globus Medical by 159.5% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 737 shares of the medical device company’s stock valued at $54,000 after buying an additional 453 shares during the period. Allworth Financial LP grew its position in shares of Globus Medical by 32,200.0% during the second quarter. Allworth Financial LP now owns 969 shares of the medical device company’s stock worth $54,000 after buying an additional 966 shares in the last quarter. Finally, Venture Visionary Partners LLC purchased a new stake in shares of Globus Medical during the second quarter worth approximately $55,000. Hedge funds and other institutional investors own 73.08% of the company’s stock.
Analysts Set New Price Targets
GMED has been the subject of several analyst reports. Barclays began coverage on shares of Globus Medical in a report on Monday, October 17th. They set an “overweight” rating and a $69.00 price target for the company. Piper Sandler dropped their target price on Globus Medical from $80.00 to $75.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. StockNews.com raised Globus Medical from a “hold” rating to a “buy” rating in a report on Friday, November 11th. Jefferies Financial Group started coverage on Globus Medical in a research report on Wednesday, October 12th. They set a “buy” rating and a $75.00 target price on the stock. Finally, Morgan Stanley boosted their target price on Globus Medical from $66.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $75.08.
Globus Medical Stock Up 2.6 %
Globus Medical Profile
Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.
- Get a free copy of the StockNews.com research report on Globus Medical (GMED)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.